login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Is magnetic resonance imaging a useful tool to identify the cause of malignant ventricular arrhythmias?


Tuesday, 27 Mar 2012 12:30
James White
James White


By James White


Approximately 5–6% of deaths occurring annually in North America are classified as sudden cardiac death, a designation indicating its occurrence within one hour of symptom onset. Patients with resuscitated sudden cardiac death or sustained (>30 seconds) ventricular tachycardia represent a particularly high-risk population for future sudden cardiac death and typically undergo a battery of testing in an attempt to identify a clear precipitant of the event. This is typically inclusive of echocardiography, invasive angiography and the selective use of other more specialised imaging tests. However, the diagnostic yield of cardiac imaging in this clinical setting has not been evaluated.


Cardiovascular magnetic resonance (CMR) imaging has evolved to provide comprehensive evaluations of cardiac morphology, function and tissue health. The latter, inclusive of T2-weighted “oedema” imaging, T1-weighted “fat” imaging, and delayed enhancement “scar” imaging provides a potentially robust platform for the evaluation of arrhythmia substrate. In our recent publication (White J A,
et al Circulation: Cardiovascular Imaging [2012] 5:12–20) we evaluated the diagnostic yield of CMR imaging versus all other clinically ordered imaging tests among a consecutive series of 82 patients presenting with resuscitated sudden cardiac death or ventricular tachycardia.


Patients with clinical evidence of ischaemia were excluded. The study identified that the detection of any relevant cardiac abnormality by non-CMR imaging was modest at 49% patients. Conversely, CMR identified relevant disease in 74% of patients, offering incremental detection of acute myocardial injury (i.e. associated with oedema) in 17% as well as the detection of unrecognised chronic myocardial disease. In those having resuscitated sudden cardiac death up to one-third of patients had evidence of acute tissue injury.


The tissue pathologies uniquely identified by CMR in this population were subendocardial-based ischaemic injury and subepicardial-based inflammatory injury; each identified both with and without associated oedema, a measure of disease acuity.


CMR was effective at identifying patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) but also identified patients with other chronic injury patterns within the right ventricle attributable to inflammatory myocarditis.


This represents the first evaluation of diagnostic utility for cardiac imaging in patients presenting with ventricular arrhythmias. While recognising that contemporary advancements in non-CMR imaging, such as echocardiography-based strain imaging, were not evaluated, the study does identify that routine clinical non-CMR imaging may neglect relevant cardiac pathology in this cohort and accrues a relatively modest diagnostic yield. The use of CMR imaging achieved a more robust diagnostic yield and did so through its unique identification of tissue level pathology. Most importantly, acute tissue injury was identified in a significant number of patients.


The clinical relevance of re-classifying patients with respect to the presence of acute tissue injury by CMR is yet uncertain and requires ongoing study. By convention, clinically recognised acute ischaemic injury is considered sufficient justification of a transient arrhythmia precipitant to negate need for secondary prevention implantable cardiac defibrillator therapy. However, whether or not sub-clinical CMR evidence of the same should carry a similar recommendation is an interesting and debatable question. Accordingly, there is a need for prospective clinical trials and registries in this field to assist in answering these important clinical questions.


James White is a cardiologist, C
ardiovascular MRI Clinical Research Program, MRI Unit, Robarts Research Institute, London, Canada.

 




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

French hospital celebrates 30 years of implanting artificial hearts
Wednesday, 13 Apr 2016
La Pitié-Salpêtrière Hospital (Paris, France), the world’s leading artificial heart centre, is celebrating the 30th anniversary of the first Total Artificial Heart implantation. The centre has now ... French hospital celebrates 30 years of implanting artificial hearts

Tuesday, 05 Apr 2016
One-month, follow-up patient cohort data from the Revelution trial of Medtronic’s novel drug-filled stent indicate that device is associated with rapid vessel healing without inflammation, as ... Early data show good rapid healing for Medtronic’s investigational drug-filled stent

Features


Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy
Monday, 09 May 2016
According to Usman Baber, TWILIGHT is a unique and innovative study in that the experimental intervention is to withdraw rather than add to existing background pharmacotherapy. In this commentary, he ... Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy

The role of sutureless and rapid-deployment valves
Tuesday, 05 Apr 2016
Antonio Miceli explores the data for sutureless and rapid-deployment surgical valves for the management of patients with severe aortic stenosis. He also reviews the place of these new devices ... The role of sutureless and rapid-deployment valves

Profiles


Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions